 Home > Medical News > Latest Medical News > Huadong Medicine's Class 1 new drug IMGN853 was approved for a pivotal single-arm clinical trial

Huadong Medicine's Class 1 new drug IMGN853 was approved for a pivotal single-arm clinical trial

 Last Update: 2021-06-01
 Source: Internet
 Author: User

Tags

india united states

capsaicin cancer

immunotherapy cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On May 28, Huadong Medicine issued an announcement stating that its wholly-owned subsidiary received the "Notice of Acceptance" approved and issued by the State Food and Drug Administration.

ImmunoGen has completed the global key single-arm study enrollment in May this year, and it is expected to submit IMGN853's listing application in the United States in the first quarter of 2022.

The accepted one is a pivotal single-arm clinical trial in China.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.